

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Shigeru Akasofu et al.

Application No.: 10/560,179

Confirmation No.: 7982

Filed: December 9, 2005

Art Unit: 1617

For: NEUROCYTE PROTECTIVE AGENT

Examiner: Deirdre R. Claytor

**RESPONSE TO RESTRICTION REQUIREMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Office Action mailed April 23, 2007. The Examiner has required restriction to one of the following four claim groups:

- Group 1:** Claims 1-12, drawn to a protective agent for neurons of the central nervous system, comprising any one of the compounds shown in (i) to (vii);
- Group 2:** Claims 13-19, drawn to a method of protecting neurons of the central nervous system, comprising administering the protective agent of Group 1;
- Group 3:** Claims 21, 22, and 24-26, drawn to a method of screening for a compound with A $\beta$  aggregation inhibitory effect; and
- Group 4:** Claims 23 and 27, drawn to a screening kit for a compound with A $\beta$  aggregation inhibitory effect.

Applicant hereby elects Group 2 (claims 13-19) for prosecution on the merits. This election is made without traverse.

Applicant hereby elects 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl]methylpiperidine, or a pharmacologically acceptable salt thereof, as the agent species, and Aβ toxicity as the disorder species.


Claims 13, 14, 15, and 18 read on the elected claims and species.

**Conclusion**

It is believed that this paper is fully responsive to the outstanding requirement for claim and species election. Accordingly, consideration of these remarks is respectfully requested.

Dated: May 23, 2007

Respectfully submitted,

By   
Paul M. Zagar

Registration No.: 52,392  
DARBY & DARBY P.C.  
P.O. Box 5257  
New York, New York 10150-5257  
(212) 527-7700  
(212) 527-7701 (Fax)  
Attorneys/Agents For Applicant